Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Turn Therapeutics Inc (TTRX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$8.94-8.78%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for TTRX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Expand board with independent directors for better governance | New board members improve leadership. | Intact | No new independent directors added within next 4 quarters | Qualitative condition This condition has no defined numerical measure. Nov 5, 2026Last status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative clinical-stage biotech, not a proven durable compounder. The long-term thesis is intact, but confidence is low and the risk level is high.
The evidence does not provide a peer valuation comparison or a clear account of what expectations are reflected in the valuation. TTRX is loss-making, so the available evidence does not support a firm view on whether it is cheap, fair, or expensive.
Near term, management says GX-03's Phase 2 atopic dermatitis trial is on track, with enrollment expanded to 120-135 patients and completion planned by the end of 2026. Cash of $10.3 million in 2026-Q2 was reported to provide runway into Q3 2027, but a recent earnings miss and equity financing activity add uncertainty.
Over the next one to three years, the thesis depends on trial progress and whether the planned expansion into other indications advances. The wider Healthcare sector is a near-term tailwind, but weakening jobs data or poorer results and guidance from sector bellwethers could weaken that support.
The multi-year view rests on GX-03 development and the company's ability to fund its plans, with high risk and low confidence in the evidence. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A supporting condition in Turn Therapeutics Inc's published investment case. The stated target is Maintain loan agreements and financial obligations without default. |
| Intact |
| Default or failure to manage financial obligations within next 4 quarters |
No default reported No default events. Recent private placement and warrant issuance indicate active capital management. Nov 5, 2026Last status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Operating income loss stays near or below -$1.25 million | They manage losses near $1.2 million operating loss in 2026-Q1. | Under Pressure | Operating income loss worsens beyond -$1,250,000 next quarter | Operating income: $-1.628M FY2026-Q2; GAAP. Published target: Operating income loss <= -$1,250,000. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 12, 2026-1,628,060 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “Based on Company’s estimate, the cash and cash equivalents on hand as of June 30, 2026 provide operational runway, including the ongoing Phase 2 trial in AD, into the third quarter of 2027.” “Based on Company’s estimate, the cash and cash equivalents on hand as of June 30, 2026 provide operational runway, including the ongoing Phase 2 trial in AD, into the third quarter of 2027.” Delivery assessment Nov 5, 2026 |
Positive clinical study results support product viability | Turn Therapeutics shows progress with a new drug study. | Intact | No positive clinical results published within next 4 quarters | Positive results published News confirms Turn Therapeutics published GX-03 dermatitis study results on 2026-05-27, advancing the Phase 2 trial in atopic dermatitis. Nov 5, 2026Last status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.32 → $-0.42 · observed estimates
$0.01B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.32 | $5,000,000 | 1 / 1 |
| 2026-07-25 | $-0.32 | $5,000,000 | 1 / 1 |
| 2026-07-26 | $-0.32 | $5,000,000 | 1 / 1 |
| 2026-07-27 | $-0.32 | $5,000,000 | 1 / 1 |
| 2026-07-28 | $-0.32 | $0 | 1 / 1 |
| 2026-07-29 | $-0.32 | $0 | 1 / 1 |
| 2026-07-30 | $-0.32 | $0 | 1 / 1 |
| 2026-07-31 | $-0.32 | $5,000,000 | 1 / 1 |
| 2026-08-01 | $-0.32 | $5,000,000 | 1 / 1 |
| 2026-08-02 | $-0.32 | $0 | 1 / 1 |
| 2026-08-03 | $-0.32 | $0 | 1 / 1 |
| 2026-08-04 | $-0.32 | $5,000,000 | 1 / 1 |
| 2026-08-05 | $-0.32 | $0 | 1 / 1 |
| 2026-08-06 | $-0.32 | $5,000,000 | 1 / 1 |
| 2026-08-08 | $-0.32 | $5,000,000 | 1 / 1 |
| 2026-08-09 | $-0.32 | $0 | 1 / 1 |
| 2026-08-10 | $-0.32 | $0 | 1 / 1 |
| 2026-08-12 | $-0.32 | $0 | 1 / 1 |
| 2026-08-13 | $-0.32 | $5,000,000 | 1 / 1 |
| 2026-08-14 | $-0.32 | $5,000,000 | 1 / 1 |
| 2026-08-15 | $-0.32 | $5,000,000 | 1 / 1 |
| 2026-08-16 | $-0.32 | $5,000,000 | 1 / 1 |
| 2026-08-17 | $-0.32 | $5,000,000 | 1 / 1 |
| 2026-08-18 | $-0.32 | $5,000,000 | 1 / 1 |
| 2026-08-19 | $-0.32 | $5,000,000 | 1 / 1 |
| 2026-08-20 | $-0.39 | $5,000,000 | 1 / 1 |
| 2026-08-21 | $-0.39 | $5,000,000 | 1 / 1 |
| 2026-08-22 | $-0.39 | $5,000,000 | 1 / 1 |
| 2026-08-23 | $-0.39 | $5,000,000 | 1 / 1 |
| 2026-08-24 | $-0.39 | $5,000,000 | 1 / 1 |
| 2026-08-25 | $-0.39 | $5,000,000 | 1 / 1 |
| 2026-08-26 | $-0.39 | $5,000,000 | 1 / 1 |
| 2026-08-27 | $-0.39 | $5,000,000 | 1 / 1 |
| 2026-08-28 | $-0.39 | $5,000,000 | 1 / 1 |
| 2026-08-29 | $-0.39 | $5,000,000 | 1 / 1 |
| 2026-08-30 | $-0.39 | $5,000,000 | 1 / 1 |
| 2026-08-31 | $-0.39 | $5,000,000 | 1 / 1 |
| 2026-09-01 | $-0.39 | $5,000,000 | 1 / 1 |
| 2026-09-02 | $-0.39 | $5,000,000 | 1 / 1 |
| 2026-09-03 | $-0.39 | $5,000,000 | 1 / 1 |
| 2026-09-04 | $-0.39 | $5,000,000 | 1 / 1 |
| 2026-09-05 | $-0.39 | $5,000,000 | 1 / 1 |
| 2026-09-06 | $-0.39 | $5,000,000 | 1 / 1 |
| 2026-09-07 | $-0.39 | $5,000,000 | 1 / 1 |
| 2026-09-08 | $-0.39 | $5,000,000 | 1 / 1 |
| 2026-09-09 | $-0.39 | $5,000,000 | 1 / 1 |
| 2026-09-10 | $-0.39 | $5,000,000 | 1 / 1 |
| 2026-09-11 | $-0.39 | $5,000,000 | 1 / 1 |
| 2026-09-12 | $-0.39 | $5,000,000 | 1 / 1 |
| 2026-09-13 | $-0.39 | $5,000,000 | 1 / 1 |
| 2026-09-14 | $-0.39 | $5,000,000 | 1 / 1 |
| 2026-09-15 | $-0.38 | $5,050,000 | 1 / 1 |
| 2026-09-16 | $-0.38 | $5,050,000 | 1 / 1 |
| 2026-09-17 | $-0.38 | $5,050,000 | 1 / 1 |
| 2026-09-18 | $-0.38 | $5,050,000 | 1 / 1 |
| 2026-09-19 | $-0.38 | $5,050,000 | 1 / 1 |
| 2026-09-20 | $-0.38 | $5,050,000 | 1 / 1 |
| 2026-09-21 | $-0.38 | $5,050,000 | 1 / 1 |
| 2026-09-22 | $-0.38 | $5,050,000 | 1 / 1 |
| 2026-09-23 | $-0.38 | $5,050,000 | 1 / 1 |
| 2026-09-24 | $-0.38 | $5,050,000 | 1 / 1 |
| 2026-09-25 | $-0.42 | $3,366,667 | 1 / 2 |
| 2026-09-26 | $-0.42 | $3,366,667 | 1 / 2 |
| 2026-09-27 | $-0.42 | $3,366,667 | 1 / 2 |
| 2026-09-28 | $-0.42 | $3,366,667 | 1 / 2 |
| 2026-09-29 | $-0.42 | $3,366,667 | 1 / 2 |
| 2026-09-30 | $-0.42 | $3,366,667 | 1 / 2 |
| 2026-10-01 | $-0.42 | $3,366,667 | 1 / 2 |
| 2026-10-02 | $-0.42 | $3,366,667 | 1 / 2 |
| 2026-10-03 | $-0.42 | $3,366,667 | 1 / 2 |
| 2026-10-04 | $-0.42 | $3,366,667 | 1 / 2 |
| 2026-10-05 | $-0.42 | $3,366,667 | 1 / 2 |
| 2026-10-06 | $-0.42 | $3,366,667 | 1 / 2 |
| 2026-10-07 | $-0.42 | $3,366,667 | 1 / 2 |
| 2026-10-08 | $-0.42 | $3,366,667 | 1 / 2 |
| 2026-10-09 | $-0.42 | $3,366,667 | 1 / 2 |
| 2026-10-10 | $-0.42 | $3,366,667 | 1 / 2 |
| 2026-10-11 | $-0.42 | $3,366,667 | 1 / 2 |
| 2026-10-12 | $-0.42 | $3,366,667 | 1 / 2 |
| 2026-10-13 | $-0.42 | $3,366,667 | 1 / 2 |
| 2026-10-14 | $-0.42 | $3,366,667 | 1 / 2 |
| 2026-10-15 | $-0.42 | $3,366,667 | 1 / 2 |
| 2026-10-16 | $-0.42 | $3,366,667 | 1 / 2 |
| 2026-10-17 | $-0.42 | $3,366,667 | 1 / 2 |
| 2026-10-18 | $-0.42 | $3,366,667 | 1 / 2 |
| 2026-10-19 | $-0.42 | $3,366,667 | 1 / 2 |
| 2026-10-20 | $-0.42 | $3,366,667 | 1 / 2 |
| 2026-10-21 | $-0.42 | $3,366,667 | 1 / 2 |
| 2026-10-22 | $-0.42 | $3,366,667 | 1 / 2 |
| 2026-10-23 | $-0.42 | $3,366,667 | 1 / 2 |
| 2026-10-24 | $-0.42 | $3,366,667 | 1 / 2 |
| 2026-10-25 | $-0.42 | $3,366,667 | 1 / 2 |
| 2026-10-26 | $-0.42 | $3,366,667 | 1 / 2 |
| 2026-10-27 | $-0.42 | $3,366,667 | 1 / 2 |
| 2026-10-28 | $-0.42 | $3,366,667 | 1 / 2 |
| 2026-10-29 | $-0.42 | $3,366,667 | 1 / 2 |
| 2026-10-30 | $-0.42 | $3,366,667 | 1 / 2 |
| 2026-10-31 | $-0.42 | $3,366,667 | 1 / 2 |
| 2026-11-01 | $-0.42 | $3,366,667 | 1 / 2 |
| 2026-11-02 | $-0.42 | $3,366,667 | 1 / 2 |
| 2026-11-03 | $-0.42 | $3,366,667 | 1 / 2 |
| 2026-11-04 | $-0.42 | $3,366,667 | 1 / 2 |
| 2026-11-05 | $-0.42 | $3,366,667 | 1 / 2 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 2 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 1 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.